Oncolytics Biotech (ONCY) Competitors $0.86 -0.06 (-6.20%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.84 -0.02 (-2.14%) As of 08/8/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY vs. VIGL, AQST, ETON, ATXS, FULC, PRTA, OLMA, CYRX, CAPR, and HUMAShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Vigil Neuroscience (VIGL), Aquestive Therapeutics (AQST), Eton Pharmaceuticals (ETON), Astria Therapeutics (ATXS), Fulcrum Therapeutics (FULC), Prothena (PRTA), Olema Pharmaceuticals (OLMA), CryoPort (CYRX), Capricor Therapeutics (CAPR), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. Its Competitors Vigil Neuroscience Aquestive Therapeutics Eton Pharmaceuticals Astria Therapeutics Fulcrum Therapeutics Prothena Olema Pharmaceuticals CryoPort Capricor Therapeutics Humacyte Oncolytics Biotech (NASDAQ:ONCY) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk. Do analysts recommend ONCY or VIGL? Oncolytics Biotech currently has a consensus price target of $4.33, indicating a potential upside of 404.82%. Vigil Neuroscience has a consensus price target of $10.80, indicating a potential upside of 34.16%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Oncolytics Biotech is more favorable than Vigil Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Vigil Neuroscience 0 Sell rating(s) 10 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, ONCY or VIGL? Oncolytics Biotech has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 3.33, meaning that its share price is 233% more volatile than the S&P 500. Do institutionals and insiders believe in ONCY or VIGL? 6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by insiders. Comparatively, 18.0% of Vigil Neuroscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ONCY or VIGL more profitable? Vigil Neuroscience's return on equity of -111.70% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Oncolytics BiotechN/A -421.74% -141.63% Vigil Neuroscience N/A -111.70%-74.67% Does the media prefer ONCY or VIGL? In the previous week, Oncolytics Biotech had 5 more articles in the media than Vigil Neuroscience. MarketBeat recorded 10 mentions for Oncolytics Biotech and 5 mentions for Vigil Neuroscience. Oncolytics Biotech's average media sentiment score of 0.38 beat Vigil Neuroscience's score of 0.34 indicating that Oncolytics Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vigil Neuroscience 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, ONCY or VIGL? Vigil Neuroscience is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncolytics BiotechN/AN/A-$23.14M-$0.27-3.18Vigil NeuroscienceN/AN/A-$84.26M-$2.05-3.93 SummaryOncolytics Biotech beats Vigil Neuroscience on 8 of the 13 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.61M$2.99B$5.50B$9.72BDividend YieldN/A2.28%4.59%4.12%P/E Ratio-3.1817.1130.0224.70Price / SalesN/A329.94455.90100.54Price / CashN/A40.7324.8428.01Price / Book17.178.888.525.76Net Income-$23.14M-$54.75M$3.27B$267.05M7 Day Performance-13.29%0.01%6.14%5.08%1 Month Performance-23.01%0.64%0.07%0.61%1 Year Performance-11.52%8.71%36.43%22.83% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech2.294 of 5 stars$0.86-6.2%$4.33+404.8%-12.4%$83.61MN/A-3.1830News CoverageEarnings ReportGap UpVIGLVigil Neuroscience3.1518 of 5 stars$8.05flat$10.80+34.2%N/A$383.88MN/A0.0040News CoverageUpcoming EarningsHigh Trading VolumeAQSTAquestive Therapeutics1.8147 of 5 stars$4.02+5.2%$10.14+152.3%+13.7%$379.43M$57.56M0.00160News CoverageETONEton Pharmaceuticals1.9858 of 5 stars$14.39+1.8%$29.67+106.2%+360.8%$378.93M$39.01M0.0020News CoverageEarnings ReportAnalyst DowngradeGap UpATXSAstria Therapeutics2.1137 of 5 stars$6.89+5.0%$29.00+320.9%-33.6%$370.21MN/A0.0030News CoverageUpcoming EarningsFULCFulcrum Therapeutics1.9648 of 5 stars$6.96+1.9%$7.57+8.8%-26.7%$369.45M$80M0.00100Analyst DowngradePRTAProthena3.2292 of 5 stars$6.94+1.9%$31.50+353.9%-62.6%$366.56M$135.16M-3.34130Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionOLMAOlema Pharmaceuticals2.0686 of 5 stars$5.41+1.5%$24.50+352.9%-60.8%$364.68MN/A0.0070CYRXCryoPort3.6661 of 5 stars$7.16-1.5%$10.63+48.4%-8.1%$364.50M$228.38M-3.061,186Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionCAPRCapricor Therapeutics3.5923 of 5 stars$7.68-2.8%$22.56+193.7%+141.2%$360.85M$22.27M0.00101Trending NewsUpcoming EarningsHUMAHumacyte1.6951 of 5 stars$2.26-0.9%$11.71+418.3%-68.6%$353.67M$1.57M0.00150News CoverageUpcoming EarningsAnalyst Upgrade Related Companies and Tools Related Companies Vigil Neuroscience Competitors Aquestive Therapeutics Competitors Eton Pharmaceuticals Competitors Astria Therapeutics Competitors Fulcrum Therapeutics Competitors Prothena Competitors Olema Pharmaceuticals Competitors CryoPort Competitors Capricor Therapeutics Competitors Humacyte Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCY) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONCY Stock Alerts